Table 2.
Treatment-related toxicities potentially related to pembrolizumab
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Total (%) | |
|---|---|---|---|---|---|
| Immune related | |||||
| Rash | 6 | 0 | 0 | 0 | 6 (20.0) |
| Infusion related reaction | 1 | 4 | 0 | 0 | 5 (16.7) |
| Thyroid disorders | 1 | 2 | 0 | 0 | 3 (10) |
| Pericarditis | 0 | 1 | 0 | 0 | 1 (3.3) |
| ALT increased | 0 | 0 | 0 | 1 | 1 (3.3) |
| AST increased | 0 | 0 | 0 | 1 | 1 (3.3) |
| Bell’s palsy* | 0 | 0 | 1 | 0 | 1 (3.3) |
| Hematologic >1 patient | |||||
| Leukopenia | 5 | 1 | 0 | 0 | 6 (20.0) |
| Anemia | 7 | 2 | 0 | 0 | 9 (30.0) |
| Neutropenia | 0 | 1 | 0 | 3 | 4 (13.3) |
| Lymphopenia | 3 | 0 | 1 | 0 | 4 (13.3) |
| Other >1 patient | |||||
| Hypertension | 4 | 4 | 0 | 0 | 8 (26.7) |
| ALT increased† | 5 | 1 | 0 | 0 | 6 (20.0) |
| ALK increased | 3 | 0 | 0 | 0 | 3 (10.0) |
| AST increased† | 5 | 0 | 0 | 0 | 5 (16.7) |
| Hyperglycemia | 2 | 2 | 0 | 0 | 4 (13.3) |
| Hyponatremia | 3 | 0 | 0 | 0 | 3 (10.0) |
| Hypoalbuminemia | 1 | 1 | 0 | 0 | 2 (6.7) |
| Other metabolic‡ | 3 | 1 | 0 | 0 | 4 (13.3) |
| Nausea | 4 | 1 | 0 | 0 | 5 (16.7) |
| Constipation | 2 | 0 | 0 | 0 | 2 (6.7) |
| Diarrhea | 0 | 1 | 1 | 0 | 2 (6.7) |
| Anorexia | 2 | 0 | 0 | 0 | 2 (6.7) |
| Other gastrointestinal§ | 1 | 3 | 0 | 0 | 4 (13.3) |
| Fatigue | 4 | 0 | 0 | 0 | 4 (13.3) |
| Arthralgia | 4 | 0 | 0 | 0 | 4 (13.3) |
| Headache | 2 | 1 | 0 | 0 | 3 (10.0) |
| Myalgia | 2 | 0 | 0 | 0 | 2 (6.7) |
| Alopecia | 2 | 0 | 0 | 0 | 2 (6.7) |
| Other | 16 | 4 | 0 | 0 | 20 (66.7) |
| Total | 88 | 30 | 3 | 5 | 126 |
ALT, alanine aminotransferase; ALK, alkaline phosphatase; AST, aspartate aminotransferase.
*
Possibly immune-related.
†
Nonimmune related.
‡
Includes 1 hypernatremia (grade 1), 1 hypocalcemia (grade 2), 1 hypoglycemia (grade 1), and 1 hypokalemia (grade 1).
§
Includes 1 abdominal pain (grade 1), 1 gastroesophageal reflux (grade 2), 1 mucositis (grade 2), 1 vomiting (grade 2).